Neuroendocrine evaluation of central opiate activity in primary headache disorders
- 30 June 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 34 (1) , 29-33
- https://doi.org/10.1016/0304-3959(88)90178-9
Abstract
The evaluation of central opiate activity could be of clinical value in the diagnosis and treatment of pain syndromes. The current approach via direct measurement of endogenous opioid peptides in cerebrospinal fluid (CSF) is not devoid of side effects and cannot be used in every-day practice. As an alternative to this method, we have studied the neuroendocrine response of plasma LH to an i.v. naloxone injection in 39 headache suffers from different diagnostic subgroups, and in 12 age- and sex-matched healthy volunteers. Patients (19 females and 20 males) were affected by common migraine (CM, 11 cases), migraine with interparoxysmal headache (MIH, 9), classical migraine (CIM, 9), and chronic cluster headache (CH, 10). Headache lasted 3-36 years. Prior to naloxone challenge (4 mg i.v.), LH pulsatility was evaluated for 1 h. The next morning, the pituitary response to LH-RH (10 .mu.g i.v.) was tested in 20 patients. Plasma LH was measured by RIA in every sample. The response to the tests was evaluated as secretion area of plasma LH minus the mean basal value. Controls (497.5 .+-. 85.5 mIU/ml .times. 120 min), CIM (357.8 .+-. 78.9) and CH (450.5 .+-. 70.4) patients showed similar results, while in cases of CM (155.3 .+-. 71.7, P < 0.05) and MIH (104.1 .+-. 53.7, P < 0.01) the LH secretion after naloxone injection was significantly blunted. On the contrary, the response of LH to LH-RH was similar in controls and patient groups, thus excluding pituitary dysfunctions in this response. Given the fact that there are some limitations related to the modulatory effects of gonodal steroids, these data suggest the use of the naloxone test as a tool for exploring the central opiate activity in primary headache disorders, mainly in migraine syndromes. Indeed, the naloxone test fails in those diagnostic subgroups characterized by impaired CSF levels of endogenous opioids.This publication has 21 references indexed in Scilit:
- Plasma Methionine Enkephalin Levels — A Biological Marker for Migraine?Headache: The Journal of Head and Face Pain, 1985
- LACK OF ENDOGENOUS OPIOID INHIBITORY TONE ON LH SECRETION IN EARLY PUBERTYClinical Endocrinology, 1984
- CSF β‐endorphin and the severity of painNeurology, 1984
- Progressive impairment of CSF β-EP levels in migraine sufferersPain, 1984
- OESTRADIOL/PROGESTERONE IMBALANCE AND THE PREMENSTRUAL SYNDROMEThe Lancet, 1983
- Different patterns of central and peripheral βEP, βLPH and ACTH throughout lifePeptides, 1983
- Peripherally Administered β-Endorphin Increases Cerebrospinal Fluid Endorphin Immunoreactivity*Journal of Clinical Endocrinology & Metabolism, 1982
- Intermittent Hypoendorphinaemia in Migraine AttackCephalalgia, 1982
- Primary Headaches: Reduced Circulating β-Lipotropin and β-Endorphin Levels with Impaired Reactivity to AcupunctureCephalalgia, 1981
- Endogenous Opioids in Cerebrospinal Fluid and Blood in Idiopathic Headache SufferersHeadache: The Journal of Head and Face Pain, 1980